BeOne Medicines AG (ONC)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $46.98B
Last updated: Nov 17, 2026 at 4:15 PM ET
BeOne Medicines AG (ONC) Stock Chart
BeOne Medicines AG (ONC) has a latest price of $413.26 on Nov 17, 2026, 2.7% below its 52-week high of $424.73. Its price rose 13.0% over the past 12 months. The month-end price rose 1,014.1% over the 10 years through Oct 2026, a compound annual rate of 27.3%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $370.33 in Oct 2026 and its lowest $30.36 in Dec 2016, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart ONC with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for ONC.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price rose 9.7%, and over 6 months it rose 39.1%. The month-end price rose 98.8% over the 3 years through Oct 2026, a compound annual rate of 25.7%.
| Period | Change |
|---|---|
| 1 month | +11.6% |
| 3 months | +9.7% |
| 6 months | +39.1% |
| 12 months | +13.0% |
| 12 months, with dividends | +13.0% |
| Period | Change | Per year |
|---|---|---|
| 3 years | +98.8% | +25.7% |
| 5 years | +3.5% | +0.7% |
| 10 years | +1,014.1% | +27.3% |
Price by Year
Its best calendar year was 2017, when the price rose 221.9%, and its weakest was 2022, when it fell 18.8%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $370.33 | +21.9% |
| 2025 | $303.81 | +64.5% |
| 2024 | $184.71 | +2.4% |
| 2023 | $180.36 | -18.0% |
| 2022 | $219.94 | -18.8% |
| 2021 | $270.93 | +4.9% |
| 2020 | $258.39 | +55.9% |
| 2019 | $165.76 | +18.2% |
| 2018 | $140.26 | +43.5% |
| 2017 | $97.72 | +221.9% |
Trading Range
The price is 11.2% above its 50-day average of $371.47 and 25.8% above its 200-day average of $328.49.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $413.26 | |
| 52-week high | $424.73 | -2.7% |
| 52-week low | $253.95 | +62.7% |
| 50-day average | $371.47 | +11.2% |
| 200-day average | $328.49 | +25.8% |
Price Risk
Over 3 years, its largest fall from a peak was 31.1%.
| Measure | Value |
|---|---|
| 1-year beta | 0.67 |
| Largest fall, 1 year | -30.9% |
| Largest fall, 3 years | -31.1% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About ONC
What is ONC's 1-year price change?
BeOne Medicines AG's price rose 13.0% over the past 12 months. With dividends included, the 12-month total return was 13.0%.
What is ONC's 5-year price change?
BeOne Medicines AG's month-end price rose 3.5% over the 5 years through Oct 2026, a compound annual rate of 0.7%. These figures leave out dividends.
What is ONC's 52-week high and low?
BeOne Medicines AG's 52-week high is $424.73 and its 52-week low is $253.95. Its latest price of $413.26 on Nov 17, 2026 is 2.7% below the high.
What is ONC's beta?
BeOne Medicines AG's 1-year beta against the S&P 500 is 0.67, so its price has moved less than the market over the past year. Its largest fall from a peak over the past year was 30.9%.
Is the ONC chart free?
Yes. Advanced Charting for ONC is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
ONC pages: Overview, Charting, Statistics, Valuation, Competitors